1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
National Presto reported 2024 net sales of $388.2 million, up 13.9%, and net earnings of $41.5 million, or $5.82 per share, up 20% from 2023. Growth was led by the Defense segment, which shipped from its backlog. The company said there will be no extra dividend in 2025, citing the cash needed to build inventory for a Defense backlog that now exceeds $1 billion.
Net sales rose $47.3 million, or 13.9%, to $388.2 million from $340.9 million in 2023.
Net earnings rose to $41.5 million, or $5.82 per share, from $34.6 million, or $4.86 per share, in 2023.
Defense segment sales rose $42.3 million, or 17.5%; the Safety segment reported a loss.
The Board declared a regular 2025 dividend of $1.00 per share, and no extra dividend will be paid in 2025.
HEI reported a 2024 net loss of $1,426 million, or $11.23 per share, compared with net income of $199 million, or $1.81 per share, in 2023. The result reflects a $1,875 million utility charge for estimated wildfire liabilities from tort-related claims as of December 31, 2024; excluding special items, core income from continuing operations was $124 million, or $0.98 per share, versus $152 million, or $1.38 per share, a year earlier. The filing also cites a February 10, 2025 Hawaii Supreme Court decision that the company says clarifies the path toward resolving the Maui wildfire tort litigation, and the utility dividend to HEI remains suspended.
Full-year 2024 net loss of $1,426 million ($11.23 per share) vs. net income of $199 million ($1.81 per share) in 2023
Core income from continuing operations of $124 million ($0.98 per share) vs. $152 million ($1.38 per share) in 2023
Fourth quarter 2024 net loss of $68 million ($0.40 per share) vs. net income of $49 million ($0.44 per share) in Q4 2023
Utility recorded a $1,875 million loss from accrual of estimated wildfire liabilities as of December 31, 2024, net of insurance recoveries
Gaming and Leisure Properties reported fourth quarter 2024 total revenue of $389.6 million, up from $369.0 million a year earlier, and net income of $223.6 million, compared with $217.3 million. It also issued 2025 AFFO guidance of $1.105 billion to $1.121 billion, or $3.83 to $3.88 per diluted share and OP unit, against $3.77 reported for 2024, which gives shareholders a forward range to compare with the 2024 results.
Q4 2024 total revenue was $389.6 million, versus $369.0 million in Q4 2023; net income was $223.6 million, versus $217.3 million.
Q4 2024 diluted net income per share was $0.79, versus $0.78; AFFO was $269.7 million, versus $256.6 million.
2025 AFFO guidance is $1.105 billion to $1.121 billion, or $3.83 to $3.88 per diluted share and OP unit; full-year 2024 AFFO per share was $3.77.
Board declared a first quarter 2025 dividend of $0.76 per share, payable March 28, 2025, to holders of record on March 14, 2025.
Sunstone Hotel Investors reported sharply lower fourth-quarter and full-year 2024 profit compared with 2023, when results included a hotel sale gain. Full-year 2024 net income of $43.3 million beat the midpoint of the company's November 2024 guidance, and the company guided to 2025 net income of $46 million to $71 million. The filing also says the CEO and CFO raised their cash bonus target percentages in a February 18, 2025 amended employment agreement.
Q4 2024 net income was $0.8 million, versus $127.0 million in Q4 2023; Q4 loss per diluted share was $0.02, versus earnings of $0.60.
Full-year 2024 net income was $43.3 million, versus $206.7 million in 2023; full-year adjusted EBITDA fell 12.8% to $229.7 million.
Full-year 2024 net income of $43 million exceeded the $31 million to $41 million guidance range given on November 12, 2024.
On February 18, 2025, CEO Bryan A. Giglia's target cash bonus rose from 135% to 150% and CFO Aaron R. Reyes's from 100% to 115%.
Balchem reported fourth quarter 2024 results on February 21, 2025, with net sales of $240.0 million, up 4.9% from the prior year quarter, and GAAP net earnings of $33.6 million, up 26.0%. For the full year, net sales were $953.7 million and GAAP earnings per share were $3.93, compared with $3.35 in 2023. The filing gives no new financial guidance.
Q4 2024 net sales $240.0 million, up $11.3 million or 4.9%
Q4 GAAP diluted EPS $1.03 vs. $0.82; adjusted EPS $1.13 vs. $0.95
Full-year 2024 GAAP net earnings $128.5 million, up 18.4%; adjusted EBITDA $250.3 million, up 8.4%
Full-year free cash flow $147.2 million; company paid down $119.6 million of debt
Protagonist Therapeutics reported fourth-quarter and full-year 2024 results. Net income was $131.7 million, or $2.11 per basic share, in the fourth quarter, up from $27.3 million a year earlier, and $275.2 million for 2024, compared with a net loss of $79.0 million in 2023. The company said its cash position, including a $165.0 million milestone payment received in January 2025, should fund operations through at least the end of 2028.
Q4 2024 license and collaboration revenue was $170.6 million, versus $60.0 million in Q4 2023.
Full-year 2024 license and collaboration revenue was $434.4 million, versus $60.0 million in 2023, mainly from the Takeda agreement and the JNJ milestones.
Cash, cash equivalents and marketable securities were $559.2 million as of December 31, 2024, compared with $341.6 million a year earlier.
Topline results from the Phase 3 VERIFY rusfertide trial and the Phase 2b ANTHEM icotrokinra trial are expected in March 2025.
Brady Corporation reported fiscal 2025 second-quarter sales of $356.7 million, up 10.6% from a year earlier, with acquisitions adding 10.2 points. GAAP diluted EPS fell 7.8% to $0.83, while adjusted diluted EPS rose 7.5% to $1.00, and the company raised the low end of its full-year adjusted EPS guidance. The company also lowered its GAAP EPS guidance to $3.99 to $4.24 to reflect facility closure and reorganization costs.
Q2 net sales of $356.7 million, up 10.6%; organic sales grew 2.6%
GAAP diluted EPS of $0.83 versus $0.90; adjusted diluted EPS of $1.00 versus $0.93
Full-year adjusted EPS guidance low end raised to $4.45 from $4.40; range now $4.45 to $4.70
GAAP EPS guidance updated to $3.99 to $4.24 from $4.02 to $4.32 for facility closure costs
Atmus Filtration Technologies reported fourth-quarter and full-year 2024 results, with full-year net income of $186 million and diluted earnings per share of $2.22, compared with $171 million and $2.05 in 2023. The company also issued 2025 guidance of $1,670 million to $1,735 million in revenue and adjusted earnings per share of $2.35 to $2.60, and said $130 million remained under its $150 million share repurchase authorization as of December 31, 2024.
Full-year 2024 net sales were $1,670 million, up 2.5% from the prior year; fourth-quarter net sales were $407 million, up 1.8%.
Full-year diluted EPS was $2.22 versus $2.05 in 2023; adjusted EPS was $2.50 versus $2.31.
Fourth-quarter operating cash flow was $20 million, compared with $42 million in the fourth quarter of 2023.
2025 guidance: revenue of $1,670 million to $1,735 million, adjusted EBITDA margin of 19.0% to 20.0%, and adjusted EPS of $2.35 to $2.60.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.